Core Insights - The European Medicines Agency (EMA) has provided positive recommendations for new drug approvals from Sanofi (SNY.US) and Insmed (INSM.US) during its recent meeting [1][2] - Sanofi's drug Wayrilz (rilzabrutinib) has been recommended for the treatment of immune thrombocytopenia, while Insmed's Brinsupri is supported for treating non-cystic fibrosis bronchiectasis in patients aged 12 and older [1][2] - Sanofi's application for Rezurock for chronic graft-versus-host disease (cGVHD) was not positively reviewed, prompting the company to seek a re-evaluation [2] Sanofi - Wayrilz has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) based on the successful LUNA Phase 3 clinical trial [1] - The company expressed disappointment over the negative opinion for Rezurock, which is already available in several countries including the U.S. [2] - Sanofi's executive vice president stated the commitment to work closely with EMA to bring the therapy to EU patients [2] Insmed - Brinsupri, an oral therapy, is poised to become the first approved treatment for non-cystic fibrosis bronchiectasis in the EU if the European Commission approves the CHMP recommendation [1] Other Companies - Roche (RHHBY.US) and Biogen (BIIB.US) received CHMP support for Gazyva (Gazyvaro) for treating specific types of lupus nephritis [2] - Regeneron Pharmaceuticals (REGN.US) is expected to gain EU approval for Libtayo as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma [2] - Agios (AGIO.US) received a positive opinion for Pyrukynd (mitapivat) for treating anemia related to adult α or β thalassemia [3] - Other companies with supported indication expansions include Bristol-Myers Squibb (BMY.US), Pfizer (PFE.US), Johnson & Johnson (JNJ.US), and Novartis (NVS.US) [3]

Core Viewpoint - Changshan Pharmaceutical's stock has experienced significant volatility, with a cumulative increase of 147.69% from May 6 to June 9, 2025, which is substantially higher than the growth of its industry peers and the ChiNext Composite Index [1] Group 1: Stock Performance - The company's stock price has deviated significantly, with a cumulative increase of over 30% in the last two trading days, leading to a classification of abnormal trading activity by the Shenzhen Stock Exchange [1] - The stock's performance has been notably strong, with a total increase of 147.69% over the specified period [1] Group 2: Product Development - The application for the marketing authorization of Aibennate Injection, intended for the treatment of type 2 diabetes, has been accepted by the National Medical Products Administration and is currently under professional review [1] - There are uncertainties regarding the approval of Aibennate Injection for market launch, as there are still many subsequent steps in the review process [1] - The clinical trial application for Aibennate Injection for weight loss indications has also been accepted by the National Medical Products Administration and is under review, with uncertainties surrounding the approval of the clinical trial notification [1]